Blog
RSS FeedPosted by Michael Wonder on 07 May 2020
Japan approves Gilead Sciences' remdesivir as COVID-19 drug
7 May 2020 - Japan on Thursday approved Gilead Sciences Inc’s remdesivir as a treatment for COVID-19, making it the country’s ...
Posted by Michael Wonder on 29 Apr 2020
Japan to offer anti-flu drug Avigan to 38 countries as early as this week
29 April 2020 - Japan will begin providing the anti-flu drug Avigan for free to 38 countries as early as ...
Posted by Michael Wonder on 28 Apr 2020
Remdesivir drug to be approved for coronavirus patients in May
28 April 2020 - The government will soon approve the anti-viral drug remdesivir for treatment of coronavirus patients, Japan’s first ...
Posted by Michael Wonder on 20 Apr 2020
Avigan ingredient shortage hits Japan stockpile plan
17 April 2020 - Lack of element from China spurs to push to find domestic suppliers. ...
Posted by Michael Wonder on 15 Apr 2020
Fujifilm accelerates production of its influenza anti-viral drug Avigan for COVID-19
15 April 2020 - Fujifilm has announced that it has expanded its manufacturing capacity to significantly increase production of its ...
Posted by Michael Wonder on 30 Mar 2020
Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel for treatment of patients with certain relapsed/refractory B-cell lymphomas in Japan
30 March 2020 - Submission based on previous pivotal trial data and a phase 2 study in Japan in patients ...
Posted by Michael Wonder on 25 Mar 2020
Tepmetko (tepotinib) approved in Japan for advanced NSCLC with METex14 skipping alterations
25 March 2020 - TEPMETKO (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations. ...
Posted by Michael Wonder on 25 Mar 2020
Enhertu approved in Japan for treatment of patients with HER2 positive unresectable or metastatic breast cancer
25 March 2020 - Approval based on the pivotal DESTINY-Breast01 trial represents third approval ever under the conditional early approval system ...
Posted by Michael Wonder on 19 Mar 2020
Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma the only gene therapy for patients with spinal muscular atrophy
19 March 2020 - Reimbursement with MHLW is expected by the end of 1H20, pending agreement, Zolgensma will be available at ...
Posted by Michael Wonder on 02 Mar 2020
Japan's national insurance to cover Novartis' gene therapy Zolgensma
26 February 2020 - Japan’s national insurance plans to cover Novartis’ gene therapy drug Zolgensma. ...
Posted by Michael Wonder on 24 Feb 2020
Japan Ministry of Health, Labor and Welfare approves Opdivo (nivolumab) for the treatment of patients with unresectable advanced or recurrent oesophageal cancer
21 February 2020 - First approval of Opdivo for treatment of advanced oesophageal cancer. ...
Posted by Michael Wonder on 05 Feb 2020
Exploring the application of cost-effectiveness evaluation in the Japanese National Health Insurance System
3 February 2020 - Advances in health care due to the development and introduction of new drugs and medical devices have ...
Posted by Michael Wonder on 04 Oct 2019
Japan drug price reforms risk hurting investment: Bristol-Myers CEO
3 October 2019 - Japan’s “overly restrictive” drug pricing policies risk diverting foreign direct investment to China and other markets, ...
Posted by Michael Wonder on 18 Jun 2019
Roche wins Japan approval for personalised cancer drug Rozlytrek
18 June 2019 - Swiss drugmaker Roche’s push into personalised cancer medicines hit a milestone on Tuesday with Japanese approval ...
Posted by Michael Wonder on 21 May 2019
Extremely high drug prices should be reviewed for appropriateness
21 May 2019 - As medicine advances, a succession of highly efficacious but extremely costly therapeutic drugs have arrived on ...